Bevacizumab as a Treatment Option for Radiation-Induced Cerebral Necrosis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Andisheh B, Brahme A, Bitaraf MA, et al. Clinical and radiobiological advantages of single-dose stereotactic light-ion radiation therapy for large intracranial arteriovenous malformations. Technical note. J Neurosurg 2009;111:919–26.
Azzam EI, Yang Z, Li M, et al. The effect of human cord blood therapy on the intestinal tract of lethally irradiated mice: possible use for mass casualties. Int J Radiat Biol;86:467–75.
Castinetti F, Brue T. [Radiotherapy and radiosurgery of pituitary adenomas]. Presse Med 2009;38:133–9.
Cheung MC, Chan AS, Law SC, et al. Impact of radionecrosis on cognitive dysfunction in patients after radiotherapy for nasopharyngeal carcinoma. Cancer 2003;97:2019–26.
Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235–40.
Gonzalez J, Kumar AJ, Conrad CA, et al. Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys 2007;67:323–6.
Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009;75:156–63.
Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 2009;185:113–9.
Henzel M, Hamm K, Sitter H, et al. Comparison of stereotactic radiosurgery and fractionated stereotactic radiotherapy of acoustic neurinomas according to 3-D tumor volume shrinkage and quality of life. Strahlenther Onkol 2009;185:567–73.
Hyakkoku K, Nakajima Y, Izuta H, et al. Thalidomide protects against ischemic neuronal damage induced by focal cerebral ischemia in mice. Neuroscience 2009;159:760–9.
Kang KB, Wang TT, Woon CT, et al. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol Phys 2007;67:888–96.
Levin VA, Bidaut L, Hou P, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2010 Apr 15 [Epub ahead of print].
Liu AK, Macy ME, Foreman NK. Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 2009;75:1148–54.
Marks JE, Wong J. The risk of cerebral radionecrosis in relation to dose, time and fractionation. A follow-up study. Prog Exp Tumor Res 1985;29:210–218.
Mizumoto M, Nakayama H, Tokita M, et al. Technical considerations for noncoplanar proton-beam therapy of patients with tumors proximal to the optic nerve. Strahlenther Onkol 2010;186:36–9.
Nikitin KV, Shishkina LV, Pronin IN, et al. [Radiation necrosis after stereotactic radiosurgery for benign glioma]. Zh Vopr Neirokhir Im N N Burdenko 2009:37–42; discussion 42.
Prasanna PG, Uma Devi P. Modification of WR-2721 radiation protection from gastrointestinal injury and death in mice by 2-mercaptopropionylglycine. Radiat Res 1993;133:111–5.
Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227–34.
Sterzing F, Welzel T, Sroka-Perez G, et al. Reirradiation of multiple brain metastases with helical tomotherapy. A multifocal simultaneous integrated boost for eight or more lesions. Strahlenther Onkol 2009;185:89–93.
Torcuator R, Zuniga R, Loutfi R, et al. Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report. J Neurooncol 2009;93:409–12.
Torcuator R, Zuniga R, Mohan YS, et al. Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis. J Neurooncol 2009;94:63–8.
Tsao MN, Li YQ, Lu G, et al. Upregulation of vascular endothelial growth factor is associated with radiation-induced blood-spinal cord barrier breakdown. J Neuropathol Exp Neurol 1999;58:1051–60.
Williams KJ, Telfer BA, Shannon AM, et al. Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts. Br J Radiol 2008;81 Spec No 1:S21–7.
Wilson CM, Gaber MW, Sabek OM, et al. Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. Int J Radiat Oncol Biol Phys 2009;74:934–41.